Who is sponsoring NCT03809481?

NCT03809481 is sponsored by Aspen Global Incorporated.

What drugs are being tested in NCT03809481?

Interventions in NCT03809481: Danaparoid Sodium, Argatroban.

What condition does NCT03809481 study?

NCT03809481 studies Heparin-induced Thrombocytopenia.

Is NCT03809481 still recruiting?

NCT03809481 is currently terminated. Last updated 8 December 2022.

Last reviewed 2022-12-08 · How we verify

NCT03809481: HITSOVA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban

Terminated Phase 3 Last updated 8 December 2022

What this trial tests

Phase 3 trial testing Danaparoid Sodium in Heparin-induced Thrombocytopenia in 7 participants. Terminated before completion.

Timeline

16 May 2019

Primary endpoint
10 June 2022

10 June 2022

Quick facts

Lead sponsor	Aspen Global Incorporated
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	7
Start date	16 May 2019
Primary completion	10 June 2022
Estimated completion	10 June 2022
Sites	35 locations across Bosnia and Herzegovina, France, Italy, Russia, Serbia, Germany, Poland, Canada

Drugs / interventions tested

Danaparoid Sodium — full drug profile →
Argatroban (ARGATROBAN) — full drug profile →

Conditions studied

Heparin-induced Thrombocytopenia — all drugs for Heparin-induced Thrombocytopenia →

Sponsor

Aspen Global Incorporated

Who can join

Adults 2 Weeks to 100, any sex, with Heparin-induced Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Aspen Global Incorporated trials

Trials by the same sponsor.

NCT03841396 — A Study Comparing the Local Tolerability of Two Subcutaneous Heparins in Healthy Volunteers. · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03809481 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aspen Global Incorporated
Last refreshed: 8 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03809481.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing